Cellectis S.A. (NASDAQ:CLLS)’s traded shares stood at 1.27 million during the latest session, with the company’s beta value hitting 2.36. At the last check today, the stock’s price was $9.68, to imply a decrease of -19.47% or -$2.34 in intraday trading. The CLLS share’s 52-week high remains $34.71, putting it -258.57% down since that peak but still an impressive -22.21% since price per share fell to its 52-week low of $11.83. The company has a valuation of $560.37M, with an average of 0.17 million shares in intraday trading volume over the past 10 days and average of 155.68K shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Cellectis S.A. (CLLS), translating to a mean rating of 1.80. Of 11 analyst(s) looking at the stock, 1 analyst(s) give CLLS a Sell rating. 1 of those analysts rate the stock as Overweight while 3 advise Hold as 6 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.83.
Cellectis S.A. (NASDAQ:CLLS) trade information
After registering a -19.47% downside in the latest session, Cellectis S.A. (CLLS) has traded red over the past five days. The stock hit a weekly high of 12.89 this Thursday, 10/07/21, dropping -19.47% in its intraday price action. The 5-day price performance for the stock is -4.68%, and -16.06% over 30 days. With these gigs, the year-to-date price performance is -55.58%. Short interest in Cellectis S.A. (NASDAQ:CLLS) saw shorts transact 1.3 million shares and set a 7.04 days time to cover.
Analysts on Wall Street suggest a consensus price target of $27.71, implying an increase of 65.07% to the stock’s recent value. The extremes give us $10.00 and $50.00 for target low and target high price respectively. As such, CLLS has been trading -416.53% off suggested target high and -3.31% from its likely low.
Cellectis S.A. (CLLS) estimates and forecasts
Looking at statistics comparing Cellectis S.A. share performance against respective industry, we note that the company has underperformed competitors. Cellectis S.A. (CLLS) shares are -39.66% down over the last 6 months, with its year-to-date growth rate lower than industry average at -41.88% against 7.00%. Revenue is forecast to shrink -20.30% this quarter before jumping 49.50% for the next one. The rating firms project that company’s revenue will grow 2.70% compared to the previous financial year.
Revenue forecast for the current quarter as set by 8 analysts is $11.14 million. Meanwhile, for the quarter ending Dec 2021, a total of 8 analyst(s) estimate revenue growth to $29.71 million.Earnings reports from the last fiscal year show that sales brought in $10.02 million and $15.63 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 11.10% before jumping 90.10% in the following quarter.
Cellectis S.A. has its next earnings report out in November. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Cellectis S.A. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Cellectis S.A. (NASDAQ:CLLS)’s Major holders
Cellectis S.A. insiders hold 0.00% of total outstanding shares, with institutional holders owning 39.49% of the shares at 39.49% float percentage. In total, 39.49% institutions holds shares in the company, led by ARK Investment Management, LLC. As of Jun 29, 2021, the company held over 4.66 million shares (or 10.25% of shares), all amounting to roughly $72.08 million.
The next major institution holding the largest number of shares is Capital International Investors with 1.34 million shares, or about 2.95% of shares outstanding. As of the market price on Jun 29, 2021, these shares were worth $20.72 million.
We also have ARK ETF Tr-ARK Genomic Revolution ETF and Smallcap World Fund as the top two Mutual Funds with the largest holdings of the Cellectis S.A. (CLLS) shares. Going by data provided on Jul 30, 2021, ARK ETF Tr-ARK Genomic Revolution ETF holds roughly 4.39 million shares. This is just over 9.66% of the total shares, with a market valuation of $56.9 million. Data from the same date shows that the other fund manager holds a little less at 2.21 million, or 4.87% of the shares, all valued at about 44.75 million.